Company news

Jiangsu Lianhuan Pharmaceutical Co., Ltd. Class A (SSE:600513) news

Jiangsu Lianhuan Pharmaceutical Co., Ltd. Class A news releases on 6ix. Latest, Sep 29, 2026: "Jiangsu Lianhuan Pharmaceutical Co., Ltd."Announcement…

Jiangsu Lianhuan Pharmaceutical Co., Ltd. Class A (SSE:600513) news

Press releases & updates

"Jiangsu Lianhuan Pharmaceutical Co., Ltd."Announcement on Outline of the 2026 Semi-annual Performance Briefing

"Jiangsu Lianhuan Pharmaceutical Co., Ltd."Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026

"Jiangsu Lianhuan Pharmaceutical Co., Ltd."Announcement on Convening the 2026 Semi-annual Performance Briefing

"Jiangsu Lianhuan Pharmaceutical Co., Ltd."Semi-annual Report for 2026

"Jiangsu Lianhuan Pharmaceutical Co., Ltd."Announcement on the Addition of a Related Party Not Under Common Control and Increase of the Estimated Amount of Routine Related Party Transactions for 2026

"Jiangsu Lianhuan Pharmaceutical Co., Ltd."Announcement on Resolutions of the 26th Extraordinary Meeting of the 9th Board of Directors

"Jiangsu Lianhuan Pharmaceutical Co., Ltd."Announcement on Obtaining Drug Registration Certificate

"Jiangsu Lianhuan Pharmaceutical Co., Ltd."Announcement on the Proposed Selection of the Company and Controlled Subsidiary in the 12th Batch of National Centralized Drug Procurement

"Jiangsu Lianhuan Pharmaceutical Co., Ltd."Investor Relations Activity Record Form

"Jiangsu Lianhuan Pharmaceutical Co., Ltd."Announcement on the Company's Receipt of the Approval for Marketing of a Chemical API

"Jiangsu Lianhuan Pharmaceutical Co., Ltd."Announcement on Execution of the "Project Entry Agreement" by the Company and Its Controlled Subsidiary and the Progress of External Investment

"Jiangsu Lianhuan Pharmaceutical Co., Ltd."Announcement on Acquisition of Drug Registration Certificate by a Controlled Subsidiary

"Jiangsu Lianhuan Pharmaceutical Co., Ltd."Semi-annual Performance Forecast for 2026

"Jiangsu Lianhuan Pharmaceutical Co., Ltd."Announcement on Abnormal Fluctuations in Stock Trading

"JIANGSU LIANHUAN PHARMACEUTICAL CO., LTD."Announcement on Adjustment of Members of the Special Committees

Announcement on Implementation of Dividend Distribution for 2025

Announcement on Resignation of Deputy General Manager

Notice on Convening the 1st Extraordinary General Meeting in 2026

Announcement on Receiving Results of GMP Compliance Inspection Concerning Drugs

Announcement on Resolutions of the 2025 Annual General Meeting

Announcement on Resignation of Independent Director Upon Expiration of Term of Office

Announcement on Convening Performance Briefing for 2025 and Q1 2026

Investor Relations Activity Record Form

Announcement on the Holding Subsidiary Obtaining the Approval Notice for Drug Supplementary Application

Announcement on Unblinding Results of the Phase III Monotherapy Clinical Trial of the Company's Class 1 New Drug LH-1801 Tablets Combined with Metformin

Announcement on Unblinding Results of the Phase III Clinical Trial of Company's Class 1 New Drug LH-1801 Tablets Combined with Metformin

Announcement on the Signing of the "Project Entry Contract for the Science and Innovation Center" by with Yangzhou High-tech Industrial Development Zone

Announcement on the Execution of Daily Related Party Transactions in 2025 and the Estimated Daily Related Party Transactions in 2026

Announcement on Abnormal Fluctuations in Stock Trading

Announcement on Obtaining Drug Registration Certificate

Announcement on Obtaining a Drug Registration Certificate from the Republic of Ghana

Announcement on Increasing Capital to Wholly-owned Subsidiary

Announcement on Progress in Asset Purchase by Wholly-owned Subsidiary and Related Party Transactions

Announcement on Resolutions of the 21st Extraordinary Meeting of the 9th Board of Directors

Announcement on Obtaining Notice of Approval for Drug Clinical Trials

Announcement on Obtaining Notice of Approval for Clinical Trials of Class 2 Improved New Drug

Announcement on Obtaining an Approval for Registration of Issued Science and Technology Innovation Bonds

Announcement on Holding Subsidiary Obtaining Drug Registration Certificate

Announcement on Active Pharmaceutical Ingredient Levonorgestrel Passing the World Health Organization Prequalification

Announcement on Resolutions of the 4th Extraordinary General Meeting in 2025

Announcement on Convening the Q3 2025 Performance Briefing

Announcement on Holding Subsidiary Passing Generic Drug Consistency Evaluation

Announcement on Adding Extraordinary Proposal to the 4th Extraordinary General Meeting in 2025

Announcement on Amending the Articles of Association, and Formulating and Revising Some Governance Systems

联环药业关于拟签订重大合同暨关联交易事项的公告

Announcement on Completion of Change in the Equity Structure of Indirect Shareholders

Announcement on Active Pharmaceutical Ingredient Levonorgestrel Passing the World Health Organization Prequalification On-site Inspection

Indicative Announcement on Change in Equity Structure of Controlling Shareholder

Report for Q3 2025

Announcement on Adjusting Members of Special Committees